1 September 2017 (Friday) - ASH Newsletter

The American Society of Hematology emailed me their newsletter today:

Public Comment Period for Guidelines on Venous Thromboembolism
The American Society of Hematology (ASH) is seeking comments on draft recommendations for guidelines for venous thromboembolism (VTE):
  1. Heparin-Induced Thrombocytopenia
  2. VTE in the Context of Pregnancy
The public comment period is September 1 – October 2. Materials are available at: hematology.org/Guidelines-Public-Comment
FDA Approves Inotuzumab Ozogamicin for Rare Type of ALL
The U.S. Food and Drug Administration approved inotuzumab ozogamicin for the treatment of relapsed or refractory B-cell precursor acute lymphocytic leukemia.
President Trump Signs FDA Funding Bill
President Trump signed the FDA Reauthorization Act of 2017, which continues user-fee programs and promises more timely reviews.

Read the September issue, featuring a look at efforts to make clinical trials more inclusive, our new “How I Treat In Brief” section, and more.

No comments:

Post a Comment